日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Prophylactic Potential of Heyndrickxia coagulans Strain LMG S-24828 in an In Vitro Model of ESBL-Escherichia coli Urothelial Infection

亨氏凝结菌LMG S-24828菌株在体外ESBL大肠杆菌尿路上皮感染模型中的预防潜力

Spaggiari, Luca; Pedretti, Natalia; Behzad, Muhammad; Iseppi, Ramona; Sabia, Carla; Franzè, Maria Teresa; Cason, Carolina; Russo, Rosario; Comar, Manola; Seta, Francesco De; Ardizzoni, Andrea; Pericolini, Eva

Untargeted Metabolomic Analysis of Cell-Free Supernatants (CFSs) from Different Clinical Isolates of Saccharomyces cerevisiae and Their Effects on Candida albicans Virulence

对不同临床分离的酿酒酵母菌株的无细胞上清液(CFS)进行非靶向代谢组学分析及其对白色念珠菌毒力的影响

Spaggiari, Luca; Tedeschi, Gabriele; Benatti, Giulia; De Benedittis, Michael; Franzè, Maria Teresa; Pinetti, Diego; Pericolini, Eva; Ardizzoni, Andrea

Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data

在晚期EGFR突变型非小细胞肺癌患者中,化疗联合或不联合VEGF抑制剂治疗的疗效:一项基于重建个体患者数据的系统评价和荟萃分析

Di Federico, Alessandro; Stumpo, Sara; Danielli, Linda; Corradi, Giacomo; Ricciuti, Biagio; Pecci, Federica; Alessi, Joao V; Wang, Xinan; De Giglio, Andrea; Lo Bianco, Francesca; Mantuano, Francesco; Pantaleo, Maria A; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Ardizzoni, Andrea

Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel

劳拉替尼在ALK阳性晚期非小细胞肺癌中的非典型安全性特征:意大利专家组提供的管理建议

Ardizzoni, Andrea; Cortinovis, Diego; Gori, Bruno; Nuzzo, Amedeo; Pasello, Giulia; de Marinis, Filippo

Correction: Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism

更正:通过靶向葡萄糖代谢相关的下游信号通路,增强FGFR1抑制剂在鳞状细胞肺癌中的抗肿瘤活性

Fumarola, Claudia; Cretella, Daniele; Monica, Silvia La; Bonelli, Mara A; Alfieri, Roberta; Caffarra, Cristina; Quaini, Federico; Madeddu, Denise; Falco, Angela; Cavazzoni, Andrea; Digiacomo, Graziana; Mazzaschi, Giulia; Vivo, Valentina; Barocelli, Elisabetta; Tiseo, Marcello; Petronini, Pier Giorgio; Ardizzoni, Andrea

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS(G12C) inhibitors

具有黏液性组织学特征的肺腺癌:临床、基因组和免疫微环境特征以及基于免疫疗法和KRAS(G12C)抑制剂的治疗结果

Di Federico, A; Hong, L; Elkrief, A; Thummalapalli, R; Cooper, A J; Ricciuti, B; Digumarthy, S; Alessi, J V; Gogia, P; Pecci, F; Makarem, M; Gandhi, M M; Garbo, E; Saini, A; De Giglio, A; Favorito, V; Scalera, S; Cipriani, L; Marinelli, D; Haradon, D; Nguyen, T; Haradon, J; Voligny, E; Vaz, V; Gelsomino, F; Sperandi, F; Melotti, B; Ladanyi, M; Zhang, J; Gibbons, D L; Heymach, J V; Nishino, M; Lindsay, J; Rodig, S J; Pfaff, K; Sholl, L M; Wang, X; Johnson, B E; Jänne, P A; Rekhtman, N; Maugeri-Saccà, M; Heist, R S; Ardizzoni, A; Awad, M M; Arbour, K C; Schoenfeld, A J; Vokes, N I; Luo, J

Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study

卡铂、依托泊苷、阿特珠单抗和贝伐珠单抗一线治疗广泛期小细胞肺癌患者:GOIRC-01-2019 CeLEBrATE 研究

Lamberti, Giuseppe; Rihawi, Karim; Mazzoni, Francesca; Riccardi, Ferdinando; Follador, Alessandro; Tiseo, Marcello; Frassoldati, Antonio; Colantonio, Ida; Bonetti, Andrea; Genova, Carlo; Giardina, Donatella; Bertolini, Federica; Cinieri, Saverio; Pasello, Giulia; Brighenti, Matteo; Andrini, Elisa; Tognetto, Michele; Boni, Luca; Ardizzoni, Andrea

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

一线MET酪氨酸激酶抑制剂与免疫疗法±化疗治疗MET 14号外显子跳跃突变转移性非小细胞肺癌患者的疗效比较

Pecci, Federica; Li, Hui; Di Federico, Alessandro; Wu, Jia; Chen, Hong; Gariazzo, Eleonora; Mantuano, Francesco; Garbo, Edoardo; Aldea, Mihaela; Santo, Valentina; Gibbons, Don; Tran, Hai; Paoloni, Francesco; Rossato De Almeida, Guilherme; Metro, Giulio; De Giglio, Andrea; Gelsomino, Francesco; Wang, Xinan; Tiseo, Marcello; Rotow, Julia; Ardizzoni, Andrea; Lee, J Jack; Awad, Mark M; Addeo, Alfredo; Hong, Lingzhi; Negrao, Marcelo V; Jänne, Pasi A; Heymach, John V; Zhang, Jianjun; Ricciuti, Biagio; Le, Xiuning

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50

对于一线免疫治疗后出现原发性耐药的晚期非小细胞肺癌(NSCLC)患者,在疾病进展后联合铂类化疗,且一线免疫治疗无效,PD-L1 ≥50。

De Giglio, A; Zullo, L; Di Federico, A; Cani, M; Aldea, M; Soldato, D; Dall'Olio, F G; Mantuano, F; Sperandi, F; Favorito, V; Sadowska, A; Hendriks, L E L; Gorria, T; Mezquita, L; Tabbò, F; Novello, S; Gelsomino, F; Besse, B; Ardizzoni, A

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD).

PD-L1 和 IFN-γ 调节非小细胞肺癌 (NSCLC) 细胞可塑性,与免疫检查点抑制剂 (ICI) 介导的超进展疾病 (HPD) 相关

Angelicola Stefania, Giunchi Francesca, Ruzzi Francesca, Frascino Mariateresa, Pitzalis Mary, Scalambra Laura, Semprini Maria Sofia, Pittino Olga Maria, Cappello Chiara, Siracusa Irene, Chillico Ilaria Candida, Di Noia Martina, Turato Cristian, De Siervi Silvia, Lescai Francesco, Ciavattini Teresa, Lopatriello Giulia, Bertoli Luca, De Jonge Hugo, Iamele Luisa, Altimari Annalisa, Gruppioni Elisa, Ardizzoni Andrea, Rossato Marzia, Gelsomino Francesco, Lollini Pier-Luigi, Palladini Arianna